Enhanced targeting of mitochondrial peroxide defense by the combined use of thiosemicarbazones and inhibitors of thioredoxin reductase

Free Radical Biology and Medicine

Volumn 91, Issue , 2016, Pages 81-92

  Myers, Charles R ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b FREE RADICAL RESEARCH CENTER   (United States)

Author keywords

Auranofin; Cisplatin; Peroxiredoxin 3; Thioredoxin reductase; Thiosemicarbazones; Triapine

Indexed keywords

2,2' DIPYRIDYL N,N DIMETHYLSEMICARBAZONE; 3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; AURANOFIN; CISPLATIN; NITRIC OXIDE; PEROXIDE; PEROXIREDOXIN 1; PEROXIREDOXIN 3; SMALL INTERFERING RNA; THIOREDOXIN 2; THIOREDOXIN REDUCTASE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; 3-AMINOPYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONE; ANTINEOPLASTIC AGENT; DI-2-PYRIDYLKETONE-4,4-DIMETHYL-3-THIOSEMICARBAZONE; PRDX3 PROTEIN, HUMAN; PYRIDINE DERIVATIVE;

ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; CYTOSOL; DRUG CYTOTOXICITY; DRUG TARGETING; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; MITOCHONDRION; OVARIAN CANCER CELL LINE; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; ENZYMOLOGY; METABOLISM; OXIDATION REDUCTION REACTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; MITOCHONDRIA; OXIDATION-REDUCTION; PEROXIREDOXIN III; PYRIDINES; THIOREDOXIN-DISULFIDE REDUCTASE; THIOSEMICARBAZONES;

EID: 84951190669     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2015.12.008     Document Type: Article

References (87)

1. H.Z. Chae, H.J. Kim, S.W. Kang, and S.G. Rhee Characterization of three isoforms of mammalian peroxiredoxin that reduce peroxides in the presence of thioredoxin Diabetes Res. Clin. Pract. 45 1999 101 112
2. Z.A. Wood, E. Schroder, J. Robin Harris, and L.B. Poole Structure, mechanism and regulation of peroxiredoxins Trends Biochem. Sci. 28 2003 32 40
3. A.G. Cox, C.C. Winterbourn, and M.B. Hampton Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling Biochem. J. 425 2010 313 325
4. 2 is not reflected in its reaction with other oxidants and thiol reagents J. Biol. Chem. 282 2007 11885 11892
5. B. Manta, M. Hugo, C. Ortiz, G. Ferrer-Sueta, M. Trujillo, and A. Denicola The peroxidase and peroxynitrite reductase activity of human erythrocyte peroxiredoxin 2 Arch. Biochem. Biophys. 484 2009 146 154
6. A.G. Cox, A.V. Peskin, L.N. Paton, C.C. Winterbourn, and M.B. Hampton Redox potential and peroxide reactivity of human peroxiredoxin 3 Biochemistry 48 2009 6495 6501
7. M.P. Murphy How mitochondria produce reactive oxygen species Biochem. J. 417 2009 1 13
8. L. Raj, T. Ide, A.U. Gurkar, M. Foley, M. Schenone, X. Li, N.J. Tolliday, T.R. Golub, S.A. Carr, A.F. Shamji, A.M. Stern, A. Mandinova, S.L. Schreiber, and S.W. Lee Selective killing of cancer cells by a small molecule targeting the stress response to ROS Nature 475 2011 231 234
9. T.P. Szatrowski, and C.F. Nathan Production of large amounts of hydrogen peroxide by human tumor cells Cancer Res. 51 1991 794 798
10. D. Trachootham, J. Alexandre, and P. Huang Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov. 8 2009 579 591
11. X.J. Wu, X. Hua, and R.O.S. Targeting Targeting ROS: selective killing of cancer cells by a cruciferous vegetable derived pro-oxidant compound Cancer Biol. Ther. 6 2007 646 647
12. L.M. Bystrom, and S. Rivella Cancer cells with irons in the fire Free Radic. Biol. Med. 79 2015 337 342
13. J.X. Hu, Q. Gao, and L. Li Peroxiredoxin 3 is a novel marker for cell proliferation in cervical cancer Biomed. Rep. 1 2013 228 230
14. Y.S. Kim, J.H. Park, H.L. Lee, J.Y. Shim, Y.I. Choi, Y.J. Oh, S.S. Shin, Y.H. Choi, K.J. Park, R.W. Park, and S.C. Hwang Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung Tuberc. Respir. Dis. 59 2005 142 150
15. X.Y. Wang, H.J. Wang, and X.Q. Li Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer Tumour Biol. 34 2013 2275 2281
16. S. Han, H. Shen, M. Jung, B.S. Hahn, B.K. Jin, I. Kang, J. Ha, and W. Choe Expression and prognostic significance of human peroxiredoxin isoforms in endometrial cancer Oncol. Lett. 3 2012 1275 1279
17. Y.G. Wang, L. Li, C.H. Liu, S. Hong, and M.J. Zhang Peroxiredoxin 3 is resistant to oxidation-induced apoptosis of Hep-3b cells Clin. Transl. Oncol. 16 2014 561 566
18. H.C. Whitaker, D. Patel, W.J. Howat, A.Y. Warren, J.D. Kay, T. Sangan, J.C. Marioni, J. Mitchell, S. Aldridge, H.J. Luxton, C. Massie, A.G. Lynch, and D.E. Neal Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress Br. J. Cancer 109 2013 983 993
19. P.J. Chua, E.H. Lee, Y. Yu, G.W. Yip, P.H. Tan, and B.H. Bay Silencing the Peroxiredoxin III gene inhibits cell proliferation in breast cancer Int. J. Oncol. 36 2010 359 364
20. D.Y. Noh, S.J. Ahn, R.A. Lee, S.W. Kim, I.A. Park, and H.Z. Chae Overexpression of peroxiredoxin in human breast cancer Anticancer Res. 21 2001 2085 2090
21. D.R. Wonsey, K.I. Zeller, and C.V. Dang The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation Proc. Natl. Acad. Sci. U.S.A. 99 2002 6649 6654
22. S. Järvelä, I. Rantala, A. Rodriguez, H. Kallio, S. Parkkila, V.L. Kinnula, Y. Soini, and H. Haapasalo Specific expression profile and prognostic significance of peroxiredoxins in grade II-IV astrocytic brain tumors BMC Cancer 10 2010 104
23. J.H. Choi, T.N. Kim, S. Kim, S.H. Baek, J.H. Kim, S.R. Lee, and J.R. Kim Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas Anticancer Res. 22 2002 3331 3335
24. L. Nonn, M. Berggren, and G. Powis Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis Mol. Cancer Res. 1 2003 682 689
25. T.S. Chang, C.S. Cho, S. Park, S. Yu, S.W. Kang, and S.G. Rhee Peroxiredoxin III, a mitochondrion-specific peroxidase, regulates apoptotic signaling by mitochondria J. Biol. Chem. 279 2004 41975 41984
26. K.K. Brown, S.E. Eriksson, E.S. Arnér, and M.B. Hampton Mitochondrial peroxiredoxin 3 is rapidly oxidized in cells treated with isothiocyanates Free Radic. Biol. Med. 45 2008 494 502
27. A.G. Cox, K.K. Brown, E.S. Arnér, and M.B. Hampton The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation Biochem. Pharmacol. 76 2008 1097 1109
28. Y. Soini, K. Kahlos, U. Napankangas, R. Kaarteenaho-Wiik, M. Saily, P. Koistinen, P. Paaakko, A. Holmgren, and V.L. Kinnula Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma Clin. Cancer Res. 7 2001 1750 1757
29. S.E. Eriksson, S. Prast-Nielsen, E. Flaberg, L. Szekely, and E.S. Arnér High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy Free Radic. Biol. Med. 47 2009 1661 1671
30. D.T. Lincoln, E.M. Ali Emadi, K.F. Tonissen, and F.M. Clarke The thioredoxin-thioredoxin reductase system: over-expression in human cancer Anticancer Res. 23 2003 2425 2433
31. W.H. Watson, J.M. Heilman, L.L. Hughes, and J.C. Spielberger Thioredoxin reductase-1 knock down does not result in thioredoxin-1 oxidation Biochem. Biophys. Res. Commun. 368 2008 832 836
32. E.S. Arnér, M. Bjornstedt, and A. Holmgren 1-Chloro-2,4-dinitrobenzene is an irreversible inhibitor of human thioredoxin reductase. Loss of thioredoxin disulfide reductase activity is accompanied by a large increase in NADPH oxidase activity J. Biol. Chem. 270 1995 3479 3482
33. J. Nordberg, L. Zhong, A. Holmgren, and E.S. Arnér Mammalian thioredoxin reductase is irreversibly inhibited by dinitrohalobenzenes by alkylation of both the redox active selenocysteine and its neighboring cysteine residue J. Biol. Chem. 273 1998 10835 10842
34. J.M. Myers, W.E. Antholine, J. Zielonka, and C.R. Myers The iron-chelating drug triapine causes pronounced mitochondrial thiol redox stress Toxicol. Lett. 201 2011 130 136
35. Y. Yu, D.S. Kalinowski, Z. Kovacevic, A.R. Siafakas, P.J. Jansson, C. Stefani, D.B. Lovejoy, P.C. Sharpe, P.V. Bernhardt, and D.R. Richardson Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors J. Med. Chem. 52 2009 5271 5294
36. J. Yuan, D.B. Lovejoy, and D.R. Richardson Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment Blood 104 2004 1450 1458
37. J. Sigmond, J.A. Kamphuis, A.C. Laan, E.K. Hoebe, A.M. Bergman, and G.J. Peters The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent Biochem. Pharmacol. 73 2007 1548 1557
38. D.R. Richardson, P.C. Sharpe, D.B. Lovejoy, D. Senaratne, D.S. Kalinowski, M. Islam, and P.V. Bernhardt Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity J. Med. Chem. 49 2006 6510 6521
39. A.B. Alvero, W. Chen, A.C. Sartorelli, P. Schwartz, T. Rutherford, and G. Mor Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) induces apoptosis in ovarian cancer cells J. Soc. Gynecol. Investig. 13 2006 145 152
40. M. Whitnall, J. Howard, P. Ponka, and D.R. Richardson A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics Proc. Natl. Acad. Sci. U.S.A. 103 2006 14901 14906
41. T.B. Chaston, D.B. Lovejoy, R.N. Watts, and D.R. Richardson Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311 Clin. Cancer Res. 9 2003 402 414
42. J. Shao, B. Zhou, A.J. Di Bilio, L. Zhu, T. Wang, C. Qi, J. Shih, and Y. Yen A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase Mol. Cancer Ther. 5 2006 586 592
43. D.S. Kalinowski, and D.R. Richardson The evolution of iron chelators for the treatment of iron overload disease and cancer Pharmacol. Rev. 57 2005 547 583
44. D.S. Kalinowski, and D.R. Richardson Future of toxicology - iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy Chem. Res. Toxicol. 20 2007 715 720
45. J.M. Myers, Q. Cheng, W.E. Antholine, B. Kalyanaraman, A. Filipovska, E.S. Arnér, and C.R. Myers Redox activation of Fe(III)-thiosemicarbazones and Fe(III)-bleomycin by thioredoxin reductase: specificity of enzymatic redox centers and analysis of reactive species formation by ESR spin trapping Free Radic. Biol. Med. 60 2013 183 194
46. P.J. Jansson, C.L. Hawkins, D.B. Lovejoy, and D.R. Richardson The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: an EPR study J. Inorg. Biochem. 104 2010 1224 1228
47. R.A. Finch, M.C. Liu, A.H. Cory, J.G. Cory, and A.C. Sartorelli Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity Adv. Enzym. Regul. 39 1999 3 12
48. T.R. Daniels, T. Delgado, J.A. Rodriguez, G. Helguera, and M.L. Penichet The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer Clin. Immunol. 121 2006 144 158
49. S.V. Torti, and F.M. Torti Iron and cancer: more ore to be mined Nat. Rev. Cancer 13 2013 342 355
50. R.A. Walker, and S.J. Day Transferrin receptor expression in non-malignant and malignant human breast tissue J. Pathol. 148 1986 217 224
51. D. Hogemann-Savellano, E. Bos, C. Blondet, F. Sato, T. Abe, L. Josephson, R. Weissleder, J. Gaudet, D. Sgroi, P.J. Peters, and J.P. Basilion The transferrin receptor: a potential molecular imaging marker for human cancer Neoplasia 5 2003 495 506
52. C.A. Bunton Oxidation of α-diketones and α-keto-acids by hydrogen peroxide Nature 163 1949 444
53. A.G. Cox, J.M. Pullar, G. Hughes, E.C. Ledgerwood, and M.B. Hampton Oxidation of mitochondrial peroxiredoxin 3 during the initiation of receptor-mediated apoptosis Free Radic. Biol. Med. 44 2008 1001 1009
54. J.M. Myers, and C.R. Myers The effects of hexavalent chromium on thioredoxin reductase and peroxiredoxins in human bronchial epithelial cells Free Radic. Biol. Med. 47 2009 1477 1485
55. Q. Li, S. Sanlioglu, S. Li, T. Ritchie, L. Oberley, and J.F. Engelhardt GPx-1 gene delivery modulates NFκB activation following diverse environmental injuries through a specific subunit of the IKK complex Antioxid. Redox Signal. 3 2001 415 432
56. M. Wang, J.S. Kirk, S. Venkataraman, F.E. Domann, H.J. Zhang, F.Q. Schafer, S.W. Flanagan, C.J. Weydert, D.R. Spitz, G.R. Buettner, and L.W. Oberley Manganese superoxide dismutase suppresses hypoxic induction of hypoxia-inducible factor-1alpha and vascular endothelial growth factor Oncogene 24 2005 8154 8166
57. A. Banning, S. Deubel, D. Kluth, Z. Zhou, and R. Brigelius-Flohe The GI-GPx gene is a target for Nrf2 Mol. Cell. Biol. 25 2005 4914 4923
58. Y.J. Hu, and A.M. Diamond Role of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the response to selenium Cancer Res. 63 2003 3347 3351
59. Q. Wei, H. Jiang, Z. Xiao, A. Baker, M.R. Young, T.D. Veenstra, and N.H. Colburn Sulfiredoxin-Peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling Proc. Natl. Acad. Sci. U.S.A. 108 2011 7004 7009
60. S. Prast-Nielsen, M. Cebula, I. Pader, and E.S. Arnér Noble metal targeting of thioredoxin reductase - covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin Free Radic. Biol. Med. 49 2010 1765 1778
61. A.B. Witte, K. Anestål, E. Jerremalm, H. Ehrsson, and E.S. Arnér Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds Free Radic. Biol. Med. 39 2005 696 703
62. E.S. Arnér, H. Nakamura, T. Sasada, J. Yodoi, A. Holmgren, and G. Spyrou Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex Free Radic. Biol. Med. 31 2001 1170 1178
63. O. Rackham, A.M. Shearwood, R. Thyer, E. McNamara, S.M. Davies, B.A. Callus, A. Miranda-Vizuete, S.J. Berners-Price, Q. Cheng, E.S. Arnér, and A. Filipovska Substrate and inhibitor specificities differ between human cytosolic and mitochondrial thioredoxin reductases: implications for development of specific inhibitors Free Radic. Biol. Med. 50 2011 689 699
64. R. Engelman, P. Weisman-Shomer, T. Ziv, J. Xu, E.S. Arnér, and M. Benhar Multilevel regulation of 2-Cys peroxiredoxin reaction cycle by S-nitrosylation J. Biol. Chem. 288 2013 11312 11324
65. L.A. Esposito, J.E. Kokoszka, K.G. Waymire, B. Cottrell, G.R. MacGregor, and D.C. Wallace Mitochondrial oxidative stress in mice lacking the glutathione peroxidase-1 gene Free Radic. Biol. Med. 28 2000 754 766
66. S. Li, T. Yan, J.Q. Yang, T.D. Oberley, and L.W. Oberley The role of cellular glutathione peroxidase redox regulation in the suppression of tumor cell growth by manganese superoxide dismutase Cancer Res. 60 2000 3927 3939
67. D.N. Watkins, M.J. Garlepp, and P.J. Thompson Regulation of the inducible cyclo-oxygenase pathway in human cultured airway epithelial (A549) cells by nitric oxide Br. J. Pharmacol. 121 1997 1482 1488
68. Z.D. Liu, and R.C. Hider Design of iron chelators with therpaeutic application Coord. Chem. Rev. 232 2002 151 171
69. E.M. Hanschmann, M.E. Lonn, L.D. Schutte, M. Funke, J.R. Godoy, S. Eitner, C. Hudemann, and C.H. Lillig Both thioredoxin 2 and glutaredoxin 2 contribute to the reduction of the mitochondrial 2-Cys peroxiredoxin Prx3 J. Biol. Chem. 285 2010 40699 40705
70. M.P. Rigobello, L. Messori, G. Marcon, M.A. Cinellu, M. Bragadin, A. Folda, G. Scutari, and A. Bindoli Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions J. Inorg. Biochem. 98 2004 1634 1641
71. E.S. Arnér Focus on mammalian thioredoxin reductases - important selenoproteins with versatile functions Biochim. Biophys. Acta 1790 2009 495 526
72. M.P. Rigobello, A. Folda, M.C. Baldoin, G. Scutari, and A. Bindoli Effect of auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase Free Radic. Res. 39 2005 687 695
73. M.A. Fath, I.M. Ahmad, C.J. Smith, J. Spence, and D.R. Spitz Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism Clin. Cancer Res. 17 2011 6206 6217
74. M.H. Lewin, J.R. Arthur, R.A. Riemersma, F. Nicol, S.W. Walker, E.M. Millar, A.F. Howie, and G.J. Beckett Selenium supplementation acting through the induction of thioredoxin reductase and glutathione peroxidase protects the human endothelial cell line EAhy926 from damage by lipid hydroperoxides Biochim. Biophys. Acta 1593 2002 85 92
75. A. Bindoli, M.P. Rigobello, G. Scutari, C. Gabbiani, A. Casini, and L. Messori Thioredoxin reductase: a target for gold compounds acting as potential anticancer drugs Coord. Chem. Rev. 253 2009 1692 1707
76. I. Ott On the medicinal chemistry of gold complexes as anticancer drugs Coord. Chem. Rev. 253 2009 1670 1681
77. R.P. Regala, E.A. Thompson, and A.P. Fields Atypical protein kinase C iota expression and aurothiomalate sensitivity in human lung cancer cells Cancer Res. 68 2008 5888 5895
78. K. Anestål, and E.S. Arnér Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine J. Biol. Chem. 278 2003 15966 15972
79. K. Anestål, S. Prast-Nielsen, N. Cenas, and E.S. Arner Cell death by SecTRAPs: thioredoxin reductase as a prooxidant killer of cells Plos ONE 3 2008 e1846
80. Q. Cheng, W.E. Antholine, J.M. Myers, B. Kalyanaraman, E.S. Arnér, and C.R. Myers The selenium-independent inherent pro-oxidant NADPH oxidase activity of mammalian thioredoxin reductase and its selenium-dependent direct peroxidase activities J. Biol. Chem. 285 2010 21708 21723
81. R.A. Finch, M. Liu, S.P. Grill, W.C. Rose, R. Loomis, K.M. Vasquez, Y. Cheng, and A.C. Sartorelli Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity Biochem. Pharmacol. 59 2000 983 991
82. C.A. Kunos, S. Waggoner, V. von Gruenigen, E. Eldermire, J. Pink, A. Dowlati, and T.J. Kinsella Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer Clin. Cancer Res. 16 2010 1298 1306
83. ®) in cancer patients Cancer Chemother. Pharmacol. 67 2011 393 400
84. S. Wadler, D. Makower, C. Clairmont, P. Lambert, K. Fehn, and M. Sznol Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion J. Clin. Oncol. 22 2004 1553 1563
85. K.J. Himmelstein, T.F. Patton, R.J. Belt, S. Taylor, A.J. Repta, and L.A. Sternson Clinical kinetics on intact cisplatin and some related species Clin. Pharmacol. Ther. 29 1981 658 664
86. J.M. Hansen, Y.M. Go, and D.P. Jones Nuclear and mitochondrial compartmentation of oxidative stress and redox signaling Annu. Rev. Pharmacol. Toxicol. 46 2006 215 234
87. P.J. Halvey, W.H. Watson, J.M. Hansen, Y.M. Go, A. Samali, and D.P. Jones Compartmental oxidation of thiol-disulphide redox couples during epidermal growth factor signalling Biochem. J. 386 2005 215 219